UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________________________________
FORM 6-K
___________________________________________
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of November
(Commission File Number 001-37518)
___________________________________________
Benitec Biopharma Limited
(Translation of registrant’s name into English)
___________________________________________
14/114 William Street, Melbourne, VIC, 3000, Australia
(Address of principal executive office (Address of registrant’s principal executive office)
___________________________________________
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-Fx Form 40-F¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Yes¨ Nox
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
Yes¨ Nox
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes¨ Nox
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): n/a
EXHIBIT INDEX
Exhibit | Description | |
| 99.1 | Benitec changes ADS ratio |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Benitec Biopharma Limited | ||
| Date: November 18, 2019 | By: | /s/ Megan Boston |
| Name: | Megan Boston | |
| Title: | Executive Director | |